Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine in Relapsed and Primary Refractory Hodgkin Lymphoma (LEBEN)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Fondazione Giovanni Pascale
Sponsor:
Information provided by (Responsible Party):
Antonio Pinto, Fondazione Giovanni Pascale
ClinicalTrials.gov Identifier:
NCT01412307
First received: August 3, 2011
Last updated: July 21, 2014
Last verified: July 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: July 2016
  Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)